Topics: Lockdown relaxation and economic reawakening...are we there yet? The questionable logic underlying the BCG vaccine thesis; Latest serology results; Vaccine timetables

In Europe and Asia, yes; elsewhere, not yet. The charts below show infection trends for different regions with a GDP lens. For example, in late March countries comprising almost all of European GDP were experiencing rising infections. That figure has fallen below 10%, with large portions of the region’s GDP seeing sharp infection declines since peak levels. In Asia, outbreaks were never sustained at high levels. US infection trends are rising again, but this increase is in many places the by-product of increased testing (orange segment). Infections are also picking up in South America and the Mid East. Since our trend calculation is calibrated to high frequency data, categories can change a lot on a day to basis. We will be updating these monitors daily on our web portal along with the rest of the tracking charts.

Source: Johns Hopkins University, IMF, JPMAM. April 26, 2020

Europe COVID infection monitor by GDP

Legend
- Infections rising faster than tests
- Infections rising slower than tests
- Infections falling, 100% - 85% of peak
- Infections falling, 85% - 50% of peak
- Infections falling, 50% - 25% of peak
- Infections falling, below 25% of peak
- No infections, or < 5 cases per mm

Asia COVID infection monitor by GDP

US COVID infection monitor by state GDP

M East COVID infection monitor by GDP

S America COVID infection monitor by GDP
Latest serology results (tests for COVID-19 antibodies), to be interpreted with a grain of salt

Let’s discuss caveats first (we discuss all of this in detail in Section 5 on the web portal):

- As many as one third of recovered patients in a 175-person cohort in China did not possess high levels of COVID-19 antibodies normally associated with disease recovery. Whether low-antibody patients are still susceptible to the disease remains to be determined.

- Serology manufacturers’ kits differ on “specificity” (false anti-body positive) and “sensitivity” (false anti-body negative), in which case antibody presence could be misestimated\(^1\). A study from UCSF and UC Berkeley analyzed 12 different tests and provides insight into these questions. The authors found “good to excellent sensitivity for all evaluated tests in hospitalized patients three or more weeks into their disease course”, and that their data “demonstrate specificity > 95% for the majority of tests evaluated, and > 99% for three of them”.

- There are not enough high quality serology kits yet, the FDA does not exercise quality control over them, and study sizes are very small relative to the populations they are extrapolated against.

- Some studies make adjustments for age/gender/race to the extent that the serology group differs from the broader population, which further muddies the results.

Even so, these serology markers are informative as to the progression of the virus and are better measures of infection and mortality rates than reported alternatives. Warts and all, here are the latest results.

### Serology test results to date

<table>
<thead>
<tr>
<th>Study location</th>
<th>Time from outbreak to day of serology test</th>
<th>Reported case to population ratio</th>
<th>Est. population with antibodies</th>
<th>Reported case fatality rate</th>
<th>Case fatality rate based on serology estimate</th>
<th>Study size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scotland</td>
<td>21</td>
<td>0.1%</td>
<td>1.2%</td>
<td>0.4%</td>
<td>0.04%</td>
<td>1,000</td>
</tr>
<tr>
<td>Denmark</td>
<td>35</td>
<td>0.1%</td>
<td>2.7%</td>
<td>2.2%</td>
<td>0.1%</td>
<td>1,000</td>
</tr>
<tr>
<td>Netherlands</td>
<td>49</td>
<td>1.6%</td>
<td>3.0%</td>
<td>1.5%</td>
<td>0.8%</td>
<td>7,000</td>
</tr>
<tr>
<td>NY State</td>
<td>52</td>
<td>1.4%</td>
<td>13.9%</td>
<td>7.4%</td>
<td>0.7%</td>
<td>3,000</td>
</tr>
<tr>
<td>Geneva Swi</td>
<td>52</td>
<td>0.5%</td>
<td>5.5%</td>
<td>8.8%</td>
<td>0.8%</td>
<td>760</td>
</tr>
<tr>
<td>Santa Clara</td>
<td>64</td>
<td>0.1%</td>
<td>3.3%</td>
<td>3.4%</td>
<td>0.1%</td>
<td>3,330</td>
</tr>
<tr>
<td>Gangelt Ger</td>
<td>73</td>
<td>2.4%</td>
<td>14.0%</td>
<td>2.3%</td>
<td>0.4%</td>
<td>500</td>
</tr>
<tr>
<td>Los Angeles</td>
<td>76</td>
<td>0.1%</td>
<td>4.2%</td>
<td>2.9%</td>
<td>0.1%</td>
<td>863</td>
</tr>
</tbody>
</table>

Source: JPMAM, JHU. 2020. See page 7 for serology data sources.

\(^1\) On serology tests: please do not send me emails stating that you believe that false positives outnumber actual positives unless (a) you have made an estimate of disease prevalence and can explain how that affects your results; (b) you estimate the number of actual (correct) negatives relative to false positives and are prepared to discuss the public policy implications of this comparison; and (c) you cite false positive and false negative accuracy of PCR virus testing kits, since that’s the most likely alternative/complement to serology-based reopening strategies.
The most ambitious vaccine timetables I have seen so far

Most of the news on anti-virals has been a letdown recently, particularly the Gilead/Remdesivir mess in which a paper was posted online by accident, the fact that the study was reportedly terminated due to lack of patients and the fact that more people apparently died in the Remdesivir group than in the control group. However, on the vaccine front, two large companies have announced ambitious timetables that are faster than the base case that I and many others have been assuming. I take this as a positive given their extensive experience in vaccine development, but we will have to see how the trials go. See Section 4 on the web portal for more on anti-virals and vaccines.

- **Oxford** University announced a very aggressive timetable for development of a vaccine based on a chimpanzee virus that is altered to be harmless to humans, and which includes genetic components coding for the SARS-CoV-2 spike proteins. As with other vaccine ideas, the spike proteins of the coronavirus are expected to provoke the body’s immune system into generating the necessary antibodies. Oxford’s Jenner Institute hopes to produce one million doses by the fall of 2020 if current clinical trials are successful (1,100 volunteers have been recruited into a randomized trial)
  - The Serum Institute of India, one of the world’s largest vaccine companies, actually announced that they will produce 40 million of Oxford’s vaccines now, even before trials are completed
- **J&J** announced a very ambitious timetable for a COVID-19 vaccine that uses the same technology platform as their Ebola vaccine (which took 5 years to complete). This platform is also used by J&J for its Zika, RSV, and HIV vaccine candidates which are currently in Phase 2 or Phase 3 trials. J&J aims to begin Phase I trials in September 2020 with production as early as spring 2021. They have reportedly identified a lead vaccine candidate (with two backups)
- **Other longer term vaccine initiatives** discussed on our web portal include candidates from Sanofi/GlaxoSmithKline, CanSino, BioNTech/Pfizer, Sinovac/Dynavax, Moderna and Inovio
- Keep in mind that some of these vaccine candidates are based on RNA/DNA or viral vector technologies that have never been approved for use before in vaccines used for communicable diseases
The questionable premise that the BCG vaccine is a driver of COVID severity

Some healthcare professionals have advanced the premise that the BCG vaccine (a tuberculosis vaccine given to children) somehow explains regional differences in COVID severity. In epidemiology, mathematical biology and medical communities, there’s a LOT of BCG skepticism:

• The WHO has stated that there is no medical evidence to support the BCG thesis²
• The BCG vaccine is used more widely in less developed, younger countries. As severity of COVID-19 is strongly linked to age, population distributions (or vaccines other than BCG) may be much better ways to explain cross-country differences³. It’s also an odd time to draw conclusions about cross-country BCG impacts since the virus is now rising more sharply in parts of the developing world that use it
• Chinese healthcare professionals said they did not see any variation in COVID infection or mortality rates based on BCG vaccination histories⁴
• Tuberculosis is a bacteria while SARS-CoV-2 is a virus, raising questions as to why a BCG vaccine would work in the first place
• Some studies supporting the BCG concept didn’t incorporate population heterogeneity, actual vaccination rates or differences in response rates among individuals⁵
• The key flaw: many BCG studies are derived from quick and dirty cross-country comparisons, and are prone to biases that “confuse the public”⁶. They compare groups rather than individuals, and are much less helpful in identifying what may cause or prevent disease. Cross-country comparisons are simple and don’t require a lot analysis, but are prone to “ecological fallacy” (just because you observe a correlation between average exposure and outcomes does not mean that individuals with greater exposures have a higher/lower risk of disease). We already have in hydroxychloroquine a “stunning example of policy decisions made on the basis of weak evidence”

If that’s not enough for you, see the chart on the next page.

---

² “Bacille Calmette-Guérin (BCG) vaccination and COVID-19”, WHO Science Brief, April 12, 2020
³ The Imperial College of London has made it clear in their research that % of symptomatic cases requiring hospitalization, % of hospitalized cases requiring critical care and case fatality rates closely track age distributions.
⁴ Epidemiologist Salim Karim, Columbia University Mailman School of Public Health, Adjunct Professor of Medicine at Weill Medical College of Cornell University
⁵ “Coronavirus and the tuberculosis vaccine”, Dr. M. Noon, University of Goettingen, April 21, 2020
⁶ “A Skeptic’s Guide To Ecologic Studies During A Pandemic”, Madhukar Pai, Canada Research Chair in Translational Epidemiology & Global Health, McGill University, April 22, 2020
Let’s make it even simpler. Consider reported COVID deaths per million people as a function of BCG vaccine policy (assuming that reported deaths in developing economies are accurate, which is a big “if”). Yes, as shown in the chart, there’s a cluster of low death rates in countries with long-standing BCG vaccine policies [group 1]. But analytically, the entire BCG thesis falls apart in my view for the following three very simple reasons:

- The number of countries that “never had a widespread BCG vaccine policy” [group 6] is extremely small, and its dispersion is very wide.
- There are a lot of countries that no longer use the BCG vaccine but only terminated it after 1970 [group 3]. In other words, anyone over the age of 50 in these countries had the BCG vaccine, and many of these countries have high COVID death rates anyway (e.g., France, Spain). Why?
- There’s also a cluster of countries that only instituted BCG vaccine policies after 1970, and their COVID death rates are low as well [group 5]. If that’s the case, how were their older people protected if they didn’t get the vaccine??

Given the unknowable complexity of the body’s immune system, it’s impossible to predict if the BCG vaccine will or won’t work against COVID-19, and any clinical trials conducted will be interesting to watch. I sure hope it works, like every other idea proposed. But to me, the BCG thesis so far is very sloppy science.

COVID-19 deaths per million people as a function of BCG vaccine policy
Each dot represents one of 157 countries with BCG vaccine history

Purpose of This Material: This material is for information purposes only. The views, opinions, estimates and strategies expressed herein constitutes Michael Cembalest’s judgment based on current market conditions and are subject to change without notice, and may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such.

GENERAL RISKS & CONSIDERATIONS
Any views, strategies or products discussed in this material may not be appropriate for all individuals and are subject to risks. Investors may get back less than they invested, and past performance is not a reliable indicator of future results. Asset allocation / diversification does not guarantee a profit or protect against loss. Nothing in this material should be relied upon in isolation for the purpose of making an investment decision. You are urged to consider carefully whether the services, products, asset classes (e.g. equities, fixed income, alternative investments, commodities, etc.) or strategies discussed are suitable to your needs. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. For this and more complete information, including discussion of your goals/situation, contact your J.P. Morgan representative.

NON-RELIANCE
Certain information contained in this material is believed to be reliable; however, JPM does not represent or warrant its accuracy, reliability or completeness, or accept any liability for any loss or damage (whether direct or indirect) arising out of the use of all or any part of this material. No representation or warranty should be made with regard to any computations, graphs, tables, diagrams or commentary in this material, which are provided for illustration-reference purposes only. The views, opinions, estimates and strategies expressed in this material constitute our judgment based on current market conditions and are subject to change without notice. JPM assumes no duty to update any information in this material in the event that such information changes. Views, opinions, estimates and strategies expressed herein may differ from those expressed by other areas of JPM, views expressed for other purposes or in other contexts, and this material should not be regarded as a research report. Any projected results and risks are based solely on hypothetical examples cited, and actual results and risks will vary depending on specific circumstances. Forward-looking statements should not be considered as guarantees or predictions of future events.

Nothing in this document shall be construed as giving rise to any duty of care owed to, or advisory relationship with, you or any third party. Nothing in this document shall be regarded as an offer, solicitation, recommendation or advice (whether financial, accounting, legal, tax or other) given by J.P. Morgan and/or its officers or employees, irrespective of whether or not such communication was given at your request.

J.P. Morgan and its affiliates and employees do not provide tax, legal or accounting advice. You should consult your own tax, legal and accounting advisors before engaging in any financial transactions.

LEGAL ENTITY, BRAND & REGULATORY INFORMATION
In the United States, bank deposit accounts and related services, such as checking, savings and bank lending, are offered by JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A. and its affiliates (collectively “JPMCB”) offer investment products, which may include bank-managed investment accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC (“JPM”), a member of FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPM and CIA are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

In Luxembourg, this material is issued by J.P. Morgan Bank Luxembourg S.A. (JPMBL), with registered office at European Bank and Business Centre, 6 route de Treves, L-2633, Senningerberg, Luxembourg. R.C.S Luxembourg B10958. Authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A. is authorized as a credit institution in accordance with the Law of 5th April 1993. In the United Kingdom, this material is issued by J.P. Morgan Bank Luxembourg S.A.—London Branch. Prior to Brexit, (Brexit meaning that the UK leaves the European Union under Article 50 of the Treaty on European Union, or, if later, loses its ability to passport financial services between the UK and the remainder of the EEA), J.P. Bank Luxembourg S.A.—London Branch is subject to limited regulation by the Financial Conduct Authority and the Prudential Regulation Authority. Details about the extent of our regulation by the Financial Conduct Authority and the Prudential Regulation Authority are available from us on request. In the event of Brexit, in the UK, J.P. Morgan Bank Luxembourg S.A.—London Branch is authorised by the Prudential Regulation Authority, subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. In Spain, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Sucursal en España, with registered office at Paseo de la Castellana, 31, 28046 Madrid, Spain. J.P. Morgan Bank Luxembourg S.A., Sucursal en España is registered under number 1516 within the administrative registry of the Bank of Spain and supervised by the Spanish Securities Market Commission (CNMV). In Germany, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Frankfurt Branch, registered office at Taunustor 1 (TaunusTurm), 60310 Frankfurt, Germany, jointly supervised by the Commission de Surveillance du Secteur Financier (CSSF) and the European Central Bank (ECB), and in certain areas also supervised by the Bundesanstalt für Finanzdienstleistungsüberwachung (BaFin). In Italy, this material is distributed by J.P. Morgan Bank Luxembourg S.A— Milan Branch, registered office at Via Catena Adalberto 4, Milan 20121, Italy and regulated by Bank of Italy and the Commissione Nazionale per le Società e la Borsa (CONSOB). In the Netherlands, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch, with registered office at World Trade Centre, Tower B, Strawinskylaan 1135, 1077 XX, Amsterdam, The Netherlands. J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF in Luxembourg. J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is also authorised and supervised by De Nederlandsche Bank (DNB) and the Autoriteit voor Financieel Onderzoek, Inspectie en Beleidsaanbevelingen (AFM) in the Netherlands. Registered with the Kamer van Koophandel as a branch of J.P. Morgan Bank Luxembourg S.A. under registration number 71651845. In Denmark, this material is distributed by J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. with registered office at Kalvebod Brygge 39-41, 1560 København V, Denmark. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A.is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg, Copenhagen Br is also subject to the supervision of Finansinspektionen (Swedish FSA). Registered with Finansinspektionen as a branch of J.P. Morgan Bank Luxembourg S.A.. In France, this material is distributed by JPMorgan Chase Bank, N.A. (“JPMCB”), Paris branch, which is regulated by the French banking authorities Autorité de Contrôle Prudentiel et de Résolution
and Autorité des Marchés Financiers. In Switzerland, this material is distributed by J.P. Morgan (Suisse) SA, which is regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA).

In Hong Kong, this material is distributed by JPMCB, Hong Kong branch. JPMCB, Hong Kong branch is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission of Hong Kong. In Hong Kong, we will cease to use your personal data for our marketing purposes without charge if you so request. In Singapore, this material is distributed by JPMCB, Singapore branch. JPMCB, Singapore branch is regulated by the Monetary Authority of Singapore. Dealing and advisory services and discretionary investment management services are provided to you by JPMCB, Hong Kong/Singapore branch (as notified to you). Banking and custody services are provided to you by JPMCB Singapore Branch. The contents of this document have not been reviewed by any regulatory authority in Hong Kong, Singapore or any other jurisdictions. This advertisement has not been reviewed by the Monetary Authority of Singapore. JPMorgan Chase Bank, N.A., a national banking association chartered under the laws of the United States, and as a body corporate, its shareholder’s liability is limited.

JPMorgan Chase Bank, N.A. (JPMCBNA) (ABN 43 074 112 011/AFS Licence No: 238367) is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation Authority. Material provided by JPMCBNA in Australia is to “wholesale clients” only. The information contained in this material is not intended to be, and must not be, distributed or passed on, directly or indirectly, to any other person, or duplicated for any other purpose without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan representative.

This material is intended for your personal use and should not be circulated to or used by any other person, or duplicated for non-personal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan representative.

© 2020 JPMorgan Chase & Co. All rights reserved.